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Multiple sclerosis (MS) and its animal model experimental autoimmune encephalomyelitis
(EAE) are neurodegenerative diseases with characteristic inﬂammatory demyelination in
the central nervous system, including the optic nerve. Neuronal and axonal damage is
considered to be the main cause of long-term disability in patients with MS. Neuronal
loss, including retinal ganglion cell (RGC) apoptosis in eyes with optic neuritis (ON), also
occurs in EAE. However, there is signiﬁcant variability in the clinical course and level of
neuronal damage in MS and EAE.The current studies examine the mechanisms and kinet-
ics of RGC loss in C57/BL6 mice immunized with myelin oligodendrocyte glycoprotein to
induce a chronic EAE disease. Clinical progression of EAE was scored daily and vision was
assessed by optokinetic responses. At various time points, RGCs were counted and optic
nerves were examined for inﬂammatory cell inﬁltration. Almost all EAE mice develop ON
by day 15 post-immunization; however, RGC loss is delayed in these mice. No RGC loss is
detected 25 days post-immunization, whereas RGC numbers in EAE mice signiﬁcantly and
progressively decrease compared to controls from 35 to 50 days post-immunization. The
delayed time course of RGC loss is in stark contrast to that reported in relapsing EAE, as
well as in rats with chronic EAE. Results suggest that different clinical disease courses of
optic nerve inﬂammation may trigger distinct mechanisms of neuronal damage, or RGCs
in different rodent strains may have variable resistance to neuronal degeneration.
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INTRODUCTION
Multiple sclerosis (MS) is an autoimmune-mediated neurodegen-
erative disease with characteristic inﬂammatory demyelination in
the central nervous system (Constantinescu et al., 1998; Nosewor-
thy et al., 2000). It has become increasingly recognized that MS
may not be a single disease entity, but instead involve different
immunopathological processes with various clinical phenotypes
(Bettelli, 2007). The ﬁrst clinical presentation inmanyMS patients
is optic neuritis (ON; Arnold, 2005). ON manifests as an acute,
self-limited episode of optic nerve inﬂammation with decreased
vision that recovers over several weeks in the majority of patients;
however, permanent visual symptoms can persist in 40–60% of
patients, and repeat episodes of ON can lead to signiﬁcant optic
nerve atrophy (Beck et al., 2004; Arnold, 2005).
Multiple sclerosis was considered primarily a demyelinating
disease in the past, however increasing evidence suggests disease
progression and permanent disability in bothMS and ON depend
upon accumulated axon degeneration (Losseff et al., 1996; Fisher
et al., 2006). Axonal degeneration measured by retinal imaging,
including thinning of the retinal nerve ﬁber layer and decreased
macular volume, occurs in patients after a single clinical episode
of ON and correlates with the level of residual visual dysfunc-
tion (Steel and Waldock, 1998; Parisi et al., 1999; Trip et al.,
2005; Costello et al., 2006; Fisher et al., 2006). Unfortunately,
the precise mechanisms leading to this neurodegeneration remain
unknown.
Determining mechanisms underlying neurodegeneration in
MS and ON is difﬁcult due to the range of clinical and histological
manifestations seen in patients, suggesting that mechanisms may
vary between different types of MS. Research on the pathophys-
iology of MS and associated ON is enhanced by the animal
model experimental autoimmune encephalomyelitis (EAE). Dif-
ferent clinical disease courses of EAE that correlate with those seen
in MS, including chronic progressive, monophasic, and relaps-
ing/remitting, have been described and depend on the type of
immunizing myelin protein and animal strain used (Fritz et al.,
1983; Tuohy et al., 1988; Constantinescu et al., 1998; Storch
et al., 1998). C57/BL6 mice immunized with myelin oligodendro-
cyte glycoprotein (MOG) exhibit a chronic EAE course (Mendel
et al., 1995). MOG-induced EAE especially reﬂects some patho-
physiological features of MS (Storch et al., 1998), including
both an encephalitogenic T-cell response and a demyelinating
autoantibody response (Iglesias et al., 2001).
Signiﬁcant retinal ganglion cell (RGC) loss by apoptosis has
been demonstrated in several experimental models of ON. In a
mouse model of relapsing/remitting EAE, RGC loss begins within
a few days after onset of optic nerve inﬂammation (Shindler
et al., 2006, 2008), suggesting RGC axonal damage, and cell loss
is induced by inﬂammation. In contrast, RGC loss occurs much
earlier in a rat model of chronic EAE (Meyer et al., 2001; Hobom
et al., 2004), with an initial wave of RGC loss occurring before
optic nerve inﬂammation is detected, suggesting there may be
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some direct injury to RGC axons in addition to damage induced
secondary to inﬂammatory cell inﬁltration.
Although development of ON has been described in C57/BL6
EAE mice immunized with MOG (Shao et al., 2004), RGC loss
was not reported. The timing and extent of RGC loss in this
chronic mouse EAE model is examined in the current studies,
and demonstrates important differences from other experimental
ON models.
MATERIALS AND METHODS
EXPERIMENTAL ANIMALS
Female C57/BL6 mice (6–7week old) were purchased from the
Jackson Laboratory (Bar Harbor, ME, USA). Housing and treat-
ment of animals conformed to the Institutional Animal Care and
Use Committee Guidelines at the University of Pennsylvania.
RGC LABELING
Retrograde labeling of RGCs was performed using the protocol
from previous studies (Shindler et al., 2006, 2008). Brieﬂy, mice
were anesthetized intraperitoneallywith 2mgketamine (Sigma,St.
Louis, MO, USA) and 1mg xylazine (Sigma). Heads were shaved,
a mediosagittal incision was made and holes were drilled bilater-
ally through the skull above the superior colliculi. About 2.5μl
of 1.25% hydroxystilbamidine (Fluorogold; Molecular Probes,
Eugene, OR, USA) in sterile phosphate buffered saline (PBS) was
injected stereotactically into the superior colliculi.
INDUCTION OF EAE
Experimental autoimmune encephalomyelitis immunization was
performed 1week after RGC labeling to allow time for retrograde
transport of ﬂuorogold into RGC bodies. To induce EAE, mice
were anesthetized with ketamine/xylazine solution and injected
subcutaneously at two sites along the back with 0.1ml solution
containing 150μg MOG (Invitrogen, Carlsbad, CA, USA) emul-
siﬁed with complete Freund’s adjuvant (CFA; Difco, Detroit, MI,
USA) containing 2.5mg/ml mycobacterium tuberculosis (Difco).
Control mice were sham immunized with an equal volume of PBS
and CFA. MOG and control mice were injected with 200 ng per-
tussis toxin (List Biological, Campbell, CA, USA) in 0.1ml PBS on
day 0 (day of immunization) and again on day 2. Clinical progres-
sion of EAE was scored daily according to the following criteria
(Gran et al., 2002): no disease= 0; partial tail paralysis= 0.5; tail
paralysis or waddling gait= 1.0; partial tail paralysis and wad-
dling gait= 1.5; tail paralysis and waddling gait= 2.0; partial limb
paralysis= 2.5; paralysis of one limb= 3.0; paralysis of one limb
and partial paralysis of another= 3.5; paralysis of two limbs= 4.0;
moribund state= 4.5; death= 5.0.
QUANTIFICATION OF RGC NUMBERS
Retinal ganglion cell were counted as in prior studies (Shindler
et al., 2006). Mice were sacriﬁced 15, 25, 35, 40, or 50 days after
immunization. Eyes were removed and ﬁxed in 4% paraformalde-
hyde in PBS. Retinas were dissected, ﬂat mounted on glass slides,
and viewed by ﬂuorescent microscopy (Nikon Eclipse E600). Pho-
tographs of RGCs were taken in 12 standardized ﬁelds (1/6, 3/6,
5/6 of the retinal radius in each quadrant) at 20× magniﬁcation.
The number of ﬂuorescent-labeledRGCs in each ﬁeldwas counted
using Image-Pro Plus 5.0 (Media Cybernetics, Silver Spring, MD,
USA) software by an investigator who was blinded to the experi-
mental treatment.Data shown represent the total number of RGCs
counted per retina (12 pictures/retina), covering a combined total
area of 0.74mm2.
OPTIC NERVE HISTOPATHOLOGY
On the days of sacriﬁce, optic nerves were removed and ﬁxed in
4% paraformaldehyde in PBS. ONs were embedded in parafﬁn,
cut into 5μm thick longitudinal sections, and stained with hema-
toxylin and eosin. Presence of inﬂammatory cell inﬁltration in the
optic nerves was assessed by a blinded investigator similar to pub-
lished criteria (Shao et al., 2004): no inﬁltration= 0; mild cellular
inﬁltration of the optic nerve or optic nerve sheath= 1; moderate
inﬁltration= 2; severe inﬁltration= 3; massive inﬁltration= 4.
OPTOKINETIC RESPONSES
Visual function was assessed by the optokinetic tracking response
(OKR) using OptoMotry software and apparatus (Cerebral
Mechanics), as described previously (Prusky et al., 2004). Brieﬂy,
mice are placed on a platform in a closed chamber and a virtual
cylinder of a 100% contrast grating is projected at varying spatial
frequencies. Mice are observed through a camera, and the investi-
gator assesses whether the mice track the rotating cylinder. Visual
function is reﬂected by the highest spatial frequency at whichmice
track and is recorded as cycles/degree.Mice only track in one direc-
tion with each eye, therefore separate visionmeasures are recorded
for each eye by alternating the direction of rotation of the cylinder.
STATISTICS
Statistical analyses were performed by ANOVA for comparison
of RGC numbers in control eyes versus EAE eyes with and with-
out ON, and ANOVA of repeated measures for OKR responses.
To compare RGC numbers in EAE eyes with control eyes, group
means were compared by Student’s t -tests. Statistics were per-
formedusingGraphPadPrism5.0 (GraphPadSoftware,SanDiego,
CA, USA).
RESULTS
CHRONIC PROGRESSIVE COURSE OF EAE INDUCED BY MOG
C57/BL6 mice immunized with MOG developed chronic EAE
symptoms (Figure 1), similar to prior studies (Mendel et al., 1995;
Gran et al., 2002). Clinical signs of EAE began by day 8 post-
immunization, and increased over the next several days before
peaking and then reaching a plateau. A similar course of EAE was
observed in three additional experiments.
OPTIC NEURITIS IN EAE MICE
Mice were sacriﬁced 15, 25, 35, 40, or 50 days following immuniza-
tion with MOG. Optic nerves from control mice demonstrated
normal histology without presence of inﬂammatory cell inﬁltrates
(Figure 2A). Inﬂammatory cell inﬁltrates detected in most optic
nerves from MOG-immunized EAE mice conﬁrmed the pres-
ence of ON (Figure 2B), whereas optic nerves from EAE mice
that demonstrated normal histology (Figure 2C) were considered
either not to have developed ON, or to have had resolution of
inﬂammation prior to sacriﬁce. More than 80% of optic nerves
developed inﬂammation by days 15 and 25 post-immunization,
with inﬂammation remaining detectable in more than 60% of
optic nerves through day 50 (Figure 2D).
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EAE INDUCES RGC LOSS
Signiﬁcant loss of RGCs was observed in eyes from EAE mice
sacriﬁced 50 days post-immunization (Figure 3), the latest time
point examined. Retinas from control mice had an average of
960.1± 91.5 RGCs/eye (n = 8). Signiﬁcantly fewer RGCs were
present in the retinas of EAE mice, both from eyes with histo-
logical evidence of ON (592.6± 128.4 RGCs, n = 7; p = 0.00003),
FIGURE 1 | Chronic progressive course of clinical EAE. C57/BL6 mice
were immunized with MOG on day 0 and injected with pertussis toxin on
day 0 and 2. Mice were observed daily for clinical signs of EAE. Clinical EAE
was ﬁrst detected at day 8 after immunization, and increased through day
17 before reaching a chronic level. One of four experiments is shown. Data
represent average (mean±SEM) EAE score of n=6 mice.
and from eyes without ON (720.3± 77.4 RGCs, n = 3; p = 0.006).
Although a trend toward fewer RGCs was observed in the retinas
of mice of EAE with ON compared to EAE eyes without ON, the
difference was not signiﬁcant.
The onset of RGC loss in chronic EAE mice was evaluated
by quantifying RGC numbers at earlier time points; 15, 25, 35,
and 40 days post-immunization. No difference in RGC numbers
was found between control mouse eyes and EAE mouse eyes
with ON at either 15 (Figure 4A) or 25 (Figure 4B) days post-
immunization. By 35 days post-immunization, signiﬁcant RGC
loss was detected in EAE eyes with ON as compared to controls
(Figure 4C), with similar RGC loss present at day 40 (Figure 4D).
VISION LOSS IN EAE MICE
To examine whether experimental ON leads to signiﬁcant vision
loss, and determine where in the disease course vision loss occurs,
visual function was measured by OKR in a group of control and
EAE mice. Baseline OKR responses were recorded prior to immu-
nization, then repeated at several time points through day 35
post-immunization (Figure 5). OKR responses were equivalent
between control and EAE mouse eyes prior to day 30 post-
immunization, but then showed a signiﬁcant drop in vision in
EAE mouse eyes compared to control mouse eyes at both day 30
(p = 0.05) and day 35 (p = 0.019).
DISCUSSION
Results of the current studies show that immunization of C57/BL6
mice with MOG induces a chronic EAE disease course with a high
incidence of ON, consistent with prior studies (Mendel et al., 1995;
FIGURE 2 | Experimental autoimmune encephalomyelitis eyes develop
optic neuritis. C57/BL6 mice were immunized with MOG and sacriﬁced 15,
25, 35, 40, or 50 days later. Longitudinal sections of isolated optic nerves
were stained with H&E and examined for the presence of inﬂammatory cell
inﬁltrates. (A) Control optic nerve showing normal histology. (B) Foci of
increased cellularity (arrows) show mild inﬂammation observed in an EAE eye
with ON. (C) EAE optic nerve without ON. (D) Most optic nerves develop
inﬂammation by day 15 post-immunization. The percentage of eyes with optic
nerve inﬂammation is shown. Data represent the average (mean±SEM)
incidence of ON at each time point (n=3–4 separate experiments/time point,
except day 50 which represents a single experiment). Photographs (A–C)
shown at original magniﬁcation ×40.
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FIGURE 3 | Retinal ganglion cell numbers decreased in EAE eyes
50days after immunization. RGCs of C57/BL6 mice were retrogradely
labeled with ﬂuorogold by stereotactic injection into the superior colliculi.
Mice were immunized with MOG or sham injected with PBS, and were
sacriﬁced 50 days post-immunization. Dissected retina from each eye was
viewed by ﬂuorescent microscopy. Optic nerve from each eye was
examined histologically for presence of inﬂammatory cell inﬁltrates. (A)
Representative photograph shown at original magniﬁcation ×20
demonstrates numerous ﬂuorescent-labeled RGCs observed in retina from
a control (non-EAE) mouse eye. (B) Fewer RGCs found in the retina from an
EAE mouse eye. (C) RGC numbers were counted in 12 standardized ﬁelds
from each retina. The number of RGCs present in control eyes was
signiﬁcantly higher than the number of RGCs in eyes from EAE mice that
did not contain histologic evidence of ON (*p =0.006) and EAE eyes with
ON (**p =0.00003).
Shao et al., 2004). While Shao et al. (2004) previously described
the development of ON in these mice, RGC degeneration was not
investigated. Our results demonstrate that there is also a signif-
icant component of neuronal degeneration in this experimental
ON model. Interestingly, RGC loss was observed in EAE eyes with
or without histological evidence of ON. This reﬂects the likelihood
that almost all eyes did indeed develop ON, but active inﬂamma-
tion can resolve prior to sacriﬁce in some animals and therefore is
missed on histological analysis.
Retinal ganglion cell loss in this chronic EAE model is delayed
by 2weeks beyond the onset of optic nerve inﬂammation, mak-
ing it distinct from other reported experimental ON models.
In relapsing/remitting mouse EAE, signiﬁcant RGC loss occurs
within 4–5 days of the onset of optic nerve inﬂammation (Shindler
et al., 2006, 2008). Differences in the timing of RGC loss may
represent differences in themagnitude or phenotype of the inﬂam-
matory response induced by distinct antigens. Alternatively, dif-
ferent mouse strains may have varying levels of resistance to
neurodegeneration based on differential genetic backgrounds or
speciﬁc genetic mutations. Mice with the Wallerian degeneration
slow mutation, for example, demonstrate delayed axonal degen-
eration in injured peripheral nerves (Lunn et al., 1989) and in
RGCs in a model of glaucoma (Beirowski et al., 2008). Follow-
ing optic nerve crush injury in 15 different mouse strains, strain
signiﬁcantly affected the time necessary to observe RGC loss (Li
et al., 2007). The current results are consistent with the hypoth-
esis that genetic background controls inherent mechanisms of
resistance to axonal degeneration, and suggest that this relative
resistance delays the inﬂammation-induced degeneration of RGCs
in C57/BL6 mice.
Differences in the timing of RGC loss exist in other experimen-
tal ON models as well. In a chronic rat EAE model, signiﬁcant
RGC loss was measured prior to the onset of optic nerve inﬂam-
mation (Hobom et al., 2004). Similarly, in another mouse EAE
model, an increase in reactive oxygen species was detected in optic
nerve as early as 3–6 days post-immunization, well before inﬂam-
mation is detectable by histology (Qi et al., 2007). These studies
suggest that in some cases ON can induce oxidative stress that may
FIGURE 4 | Retinal ganglion cell loss occurs more than 25days
after immunization to induce EAE. RGCs were labeled with
ﬂuorogold, and mice were immunized with MOG or sham injected
with PBS. Mice were euthanized 15, 25, 35, or 40 days post-immunization
and isolated retina from each eye was viewed by ﬂuorescent
microscopy. Optic nerves were examined histologically for presence of
inﬂammatory cell inﬁltrates. (A) No difference in RGC numbers was
found between control eyes and EAE eyes with ON 15days
post-immunization. (B) No difference in RGC numbers was observed at day
25. (C) At day 35, EAE ON eyes had fewer remaining RGCs than control eyes
(*p =0.048). (D) At day 40, similar RGC loss was found in EAE ON eyes
(*p =0.026).
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FIGURE 5 |Vision decreased in EAE mice by 30days
post-immunization. OKR responses were recorded in C57/BL6 mice prior
to immunization (time 0). Vision is reported as the threshold cycles/degree
tracked on a rotating cylinder. EAE mice were immunized with MOG, and
control mice were sham injected with PBS, on day 0, and OKR responses
were recorded 15, 22, 30, and 35 days later. OKR responses were
signiﬁcantly reduced in EAE eyes as compared to control eyes at day 30
(*p =0.05) and day 35 (**p =0.019) post-immunization.
lead to direct axonal injury, but our results suggest that such direct
axonal injury is likely limited or absent in C57/BL6 MOG EAE
mice.
Since the mechanisms that trigger MS and ON in patients is
not known, the variety of mechanisms occurring in the different
available experimental ON models is important to consider when
evaluating potential new therapies. If a treatment is designed to
prevent injury by blocking inﬂammation, for example, then it may
be less likely to work in a model where injury occurs prior to
onset of inﬂammation. We and others have often used the relaps-
ing/remitting EAE model to study ON because this represents the
most common clinical disease course of MS (Noseworthy et al.,
2000). However, the delayed RGC loss reported here in chronic
murine EAE may be more similar to what occurs in ON patients,
as signiﬁcant RGC axonal loss marked by retinal nerve ﬁber layer
thinning does not occur until about 3months after onset of ON
(Costello et al., 2006). Our results suggest that there may be an
extended window of opportunity to initiate therapy with a neuro-
protective agent in this model, and therefore this is an important
ON model to consider for such studies. Interestingly, in addition
to delayed RGC loss, OKR responses demonstrated that vision
loss is delayed as well. This was not necessarily expected, since
optic nerve inﬂammation alone could have interfered with visual
function. Results suggest that the level of inﬂammation present
was insufﬁcient to reduce vision, and instead visual loss corre-
lates better with the timing of RGC loss in this experimental ON
model.
While the exact timing of RGC loss in MOG-induced EAE in
C57/BL6 mice has not been reported previously, at least one study
has used thismodel to evaluate a potential neuroprotective therapy
to preventRGC loss (Guo et al., 2011). Theydemonstrate that sper-
midine prevents loss of cells in the RGC layer 25 days after onset
of EAE, but did not examine whether RGCs were lost at earlier
time points. Their results are consistent with ours, with cell loss
occurring at a similarly late time, as EAE begins 8–10 days after
immunization, suggesting they examined RGC loss between 30
and 40 days post-immunization. Importantly, while they showed
protective effects of spermidine, mice were treated beginning at
the time of immunization, prior to onset of optic nerve inﬂam-
mation. Because our results show that RGC loss is delayed, it will
be important to go back and examine whether spermidine can
be administered after onset of optic nerve inﬂammation and exert
similar neuroprotective effects. Potential future therapies will need
to be examined in this paradigm, as patients with ON will not
present before developing symptoms associated with optic nerve
inﬂammation.
Experimental models of ON represent important tools in
advancing our understanding and developing new therapies for
ON and MS. Various models demonstrate distinct disease courses
with differences in the timing of RGC loss, but share the com-
mon feature of recapitulating the neurodegenerative aspect of
this disorder. The current results demonstrate the relatively slow
degeneration of RGCs inMOG-induced chronic EAE. This model
will likely prove important for evaluation of potential neuropro-
tective agents, as treatment can be initiated well after optic nerve
inﬂammation begins, but still before RGCs have been lost.
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